Access to affordable, high-quality medicines is a priority for healthcare systems worldwide, and the US generics market remains one of the largest opportunities for Indian pharmaceutical companies. Complex and under-penetrated generics, such as controlled substances, specialty products and critical-care injectables, face less competition and earn better margins than commodity generics.
Senores Pharmaceuticals Ltd. is positioned to benefit from this structural opportunity through its portfolio of complex generics, a fast-growing ANDA pipeline, contract development and manufacturing (CDMO) services and a newly built US manufacturing and distribution platform. Its growth strategy includes launching approved ANDAs, scaling new facilities, expanding in emerging markets and building a presence in government and institutional channels in the US.
But does Senores Pharmaceuticals Ltd. offer a compelling case for long-term investors? Let’s delve deeper.
Stock overview
| Ticker | SENORES |
| Industry/Sector | Pharmaceuticals |
| CMP | 1,173.00 |
| Market Cap (₹ Cr.) | 5,403 |
| P/E | 40.5 (Vs Industry P/E of 45.32) |
| 52 W High/Low | 1,600.00 / 706.00 |
| EPS (TTM) | 28.97 |
| Dividend Yield | 0.00% |
About Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Ltd. is an Ahmedabad-based, research-driven pharmaceutical company incorporated in 2015. It develops and manufactures specialty, under-penetrated and complex generics, critical-care injectables and APIs for regulated markets including the US, Canada and the UK, with a growing presence in emerging markets.
The company serves customers through its regulated markets, emerging markets, branded generics and CDMO/CMO businesses. Its portfolio has expanded to 64 approved ANDAs as of September 2026, supported by acquisitions and subsidiaries such as Havix Group (USA), Apnar Pharma and Ratnatris Pharmaceuticals.
Senores is also investing in new manufacturing lines, US government-channel launches and a controlled-substance pipeline. These initiatives provide opportunities to strengthen its product mix, improve margins and diversify growth beyond established formulations.
Key business segments
Senores Pharmaceuticals Ltd. operates primarily in the following key business segments:
• Regulated Markets: Complex generics and ANDA products for the US, Canada and the UK (₹136.7 Cr, about 71% of Q2 FY27 revenue).
• Emerging Markets: Branded and generic formulations sold across emerging markets through product registrations (₹38.4 Cr in Q2 FY27).
• Branded Generics (India): Domestic branded formulations (₹9.5 Cr in Q2 FY27).
• CDMO/CMO: Contract development and manufacturing with a pipeline of 41 molecules covering about 130 strengths.
• Others: Includes new businesses and ventures such as Apnar and the US platform (₹7.8 Cr in Q2 FY27).
Primary growth factors for Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Ltd. key growth drivers:
• ANDA Pipeline: The approved ANDA portfolio nearly doubled from 34 to 64 in a year, with only 23 commercialised and 41 planned launches over the next 18–24 months.
• Controlled-Substance Launches: Four to five controlled-substance launches are planned before March 2027, offering higher-margin, less competitive products.
• New Capacity: The Apnar facility, with two commercial lines in place and more being added, is expected to generate over ₹100 Cr of FY27 revenue.
• US Platform: Government-channel launches, the Amerisyn and Zoraya ventures and Havix expansion can broaden US market access from H2 FY27.
• Emerging Markets & CDMO: A large registration pipeline and CDMO molecules provide additional growth avenues.
Detailed competition analysis for Senores Pharmaceuticals Ltd.
Key financial metrics – TTM / latest quarter;
| Company | Sales (₹ Cr.) | EBITDA (₹ Cr.) | EBITDA Margin (%) | PAT (₹ Cr.) | PAT Margin (%) | P/E |
| Senores Pharmaceuticals Ltd. (TTM) | 719.00 | 209.00 | 29.1% | 137.00 | 19.1% | 40.5 |
| Senores Pharmaceuticals Ltd. (Q2 FY27) | 192.33 | 57.66 | 30.0% | 36.60 | 19.0% | 40.5 |
| Marksans Pharma Ltd. (Q2 FY27) | 940.17 | 214.30 | 22.8% | 143.50 | 15.3% | n.a. |
| Strides Pharma Science Ltd. (Q2 FY27) | 1,429.73 | 250.90 | 17.5% | 134.12 | 9.4% | n.a. |
Note: Peers are shown for the latest reported quarter (Q2 FY27) for like-for-like comparison. Strides PAT is as reported. Senores trades at a P/E of 40.5x against an industry P/E of 45.32x.
Key insights on Senores Pharmaceuticals Ltd.
• Rapid Growth: FY26 revenue grew 59% year-on-year to ₹633 crore, and H1 FY27 revenue rose 30% to ₹372.5 crore, marking nine straight quarters of double-digit growth.
• Profit Momentum: FY26 PAT more than doubled to ₹122 crore, and H1 FY27 PAT rose 31% to ₹67 crore.
• Margin Strength: EBITDA margin was 26.5% in FY26 and about 30% in Q2 FY27, with H1 FY27 EBITDA up 58% to ₹111 crore.
• Regulated Markets Focus: Regulated markets contribute about 71% of revenue and grew 28% in Q2 FY27 and 34% in H1 FY27.
• Working Capital Watch-point: Debtor days stand at about 187 and working capital days at 132, with free cash flow negative at about ₹202 crore in FY26 due to heavy capex.
Recent financial performance of Senores Pharmaceuticals Ltd. for Q2 FY27
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27 | QoQ Growth (%) | YoY Growth (%) |
| Sales (₹ Cr.) | 153.94 | 180.21 | 192.33 | 6.7% | 24.9% |
| EBITDA (₹ Cr.) | 41.69 | 53.76 | 57.66 | 7.3% | 38.3% |
| EBITDA Margin (%) | 27.1% | 29.8% | 30.0% | +15 bps | +290 bps |
| PAT (₹ Cr.) | 30.12 | 30.45 | 36.60 | 20.2% | 21.5% |
| PAT Margin (%) | 19.6% | 16.9% | 19.0% | +213 bps | -54 bps |
| Adjusted EPS (₹) | 7.03 | 6.67 | 8.57 | 28.5% | 21.9% |
Note: PAT is attributable to owners. EBITDA is derived as profit before tax plus finance cost and depreciation, minus other income.
Senores Pharmaceuticals Ltd. financial update (Q2 FY27)
Financial performance
• Revenue grew 24.9% YoY to ₹192.33 crore in Q2 FY27, the highest-ever quarterly revenue, driven by regulated markets (up 27.9% to ₹136.7 crore) and emerging markets (up 21.2% to ₹38.4 crore).
• EBITDA grew 38.3% YoY to ₹57.66 crore, with EBITDA margin expanding about 290 bps to 30.0%, supported by a better product mix and a gross margin of 65.4% (up 246 bps YoY).
• PAT grew 21.5% YoY to ₹36.60 crore, with PAT margin at 19.0%, as higher depreciation and finance costs from new capacity absorbed part of the operating gains.
• Branded Generics revenue declined to ₹9.5 crore from ₹11.9 crore, while Others rose to ₹7.8 crore from ₹3.4 crore.
• H1 FY27 revenue rose 30% to ₹372.5 crore, EBITDA rose 58% to ₹111 crore (margin about 29.8%, up ~530 bps) and PAT rose 31% to ₹67 crore.
Business highlights
• ANDA portfolio: Approved ANDAs rose to 64 as of September 2026 from 34 a year earlier, with 23 commercialised and 41 planned for launch over 18–24 months.
• Launch timing: No new ANDA was commercialised in Q2. A controlled-substance ANDA launch was delayed to end-November because the quota process takes 45–50 days.
• Apnar facility: Apnar contributed almost ₹21 crore of revenue in Q2 with capacity utilisation of about 90–100%. Two commercial lines are in place, a third is being installed and a fourth is planned before March 2027.
• US government channel: The company is targeting commercialisation of 13 ANDAs covering 41 strengths in the US government channel during H2 FY27.
• Capex approved: The board approved ₹43 crore of subsidiary capex (Havix Group ₹18 crore, Apnar ₹20 crore, and a prefilled syringe line at Ratnatris ₹5 crore).
Outlook
• Guidance maintained: Management retained FY27 guidance of 30–40% revenue growth, 50–60% PAT growth and an EBITDA margin of 30% or higher.
• Medium-term growth: Management expects annual growth of 20–25% over the following two years (FY28 and FY29).
• Approvals pipeline: Management expects 3–4 further ANDA approvals and about 12–15 supplemental ANDA approvals in Q3 FY27, with 5–7 launches per quarter over the coming six to eight quarters.
• H2 drivers: Operating leverage, controlled-substance launches, Aavis and Havix launches, a stronger Ratnatris contribution and initial sales from the Amerisyn and Zoraya ventures should support second-half profit growth.
• Funding: IPO proceeds of ₹500 crore (₹418.83 crore utilised as of September 2026) and ₹95 crore of warrant proceeds support expansion.
Recent Updates on Senores Pharmaceuticals Ltd.
• Q2 FY27 Results: Reported record revenue of ₹192 crore and EBITDA of ₹58 crore, with H1 revenue up 30% and H1 EBITDA up 58%.
• Share Price Reaction: The stock fell about 8% and 7% on 29 and 30 October after results, as revenue and EBITDA came in below broker estimates despite in-line PAT.
• Capex Approval: Approved ₹43 crore of expansion across Havix Group (USA), Apnar Pharma and Ratnatris Pharmaceuticals, including a new 2.7 million unit prefilled syringe line.
• ANDA Approvals: Received approval for one new ANDA and three supplemental ANDAs in Q2, and commercialised three sANDAs.
• Shareholding: Promoter holding stood at 45.8% as of September 2026, with FIIs rising to 6.0% and DIIs to 10.9%.
Company valuation insights – Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals is currently trading at a TTM P/E of 40.5x, below the industry P/E of 45.32x, and at about 5.4x book value. On our FY27E EPS of ₹41 and FY28E EPS of ₹53, the stock trades at about 28.6x and 22x respectively, which is reasonable given the growth guided by management.
The investment thesis is supported by Senores’ fast-growing ANDA pipeline, rising share of complex and controlled-substance products, expanding margins and new US and Indian manufacturing capacity. Only 23 of 64 approved ANDAs have been commercialised, so the pipeline provides visibility for several years of growth, while operating leverage from new capacity can lift profitability. The balance sheet remains manageable, with a debt-to-equity ratio of about 0.4x.
Using a valuation multiple of 28x FY28E EPS of ₹53, we arrive at a 12-month target price of ₹1,480, implying an upside potential of 26% from current levels. The valuation reflects the potential for successful ANDA launches, continued margin expansion and scaling of the US platform. For the near term, we maintain a 3-month target price of ₹1,300, implying an upside potential of 11% from current levels.
Major risk factors for Senores Pharmaceuticals Ltd.
• Regulatory Risk: USFDA inspections, delays in ANDA approvals or compliance issues at manufacturing sites can disrupt launches and sales.
• Launch Timing Risk: Launches of controlled substances depend on DEA quota processes, as seen in the delayed Q2 launch, and slippage can defer earnings.
• Pricing & Competition Risk: Intense price erosion in the US generics market and competition from larger players can compress margins.
• Execution Risk: Ramp-up of new facilities, acquisitions and ventures such as Apnar, Amerisyn and Zoraya may take longer or cost more than expected.
• Working Capital Risk: Debtor days of about 187 and negative free cash flow can strain the balance sheet if collections slow or capex rises.
• Valuation Risk: The stock trades at about 5.4x book value, and a miss on guidance could trigger sharp de-rating, as seen after Q2 results.
• Customer & Currency Risk: Dependence on regulated markets (about 71% of revenue) and currency swings can affect revenue and margins.
Technical analysis of Senores Pharmaceuticals Ltd. share
Senores has corrected from the ₹1,324 level before results and is consolidating around ₹1,130–₹1,175 after falling about 15% in two sessions on 29 and 30 October. The stock remains about 27% below its 52-week high of ₹1,600 and well above its 52-week low of ₹706, reflecting a strong rally over the past year.
A sustained move above ₹1,320, the level that held in mid-October, would signal improving momentum and pave the way towards ₹1,480, our 12-month fundamental target. On the downside, ₹1,130 remains the immediate support, and ₹1,100 is the key stop-loss level.
• Resistance: ₹1,320
• Support: ₹1,130 (key stop-loss ₹1,100)
Senores Pharmaceuticals Ltd. stock recommendation
If you found this helpful and want regular stock trade calls, check out my community on StockGro here:Current Stance: Buy, with a 3-month target price of ₹1,300 (11% upside) and a 12-month target price of ₹1,480 (26% upside), based on a valuation of 28x FY28E EPS of ₹53.
Why buy now?
• Strong growth visibility: Management guides 30–40% revenue growth and 50–60% PAT growth in FY27, followed by 20–25% annual growth.
• Large ANDA pipeline: Only 23 of 64 approved ANDAs are commercialised, with 41 launches planned over the next 18–24 months.
• Margin expansion: EBITDA margin of about 30% and gross margin of 65.4% are improving with a richer product mix.
• New capacity: Apnar and US facilities, with a fourth Apnar line due before March 2027, support H2 FY27 growth.
• Post-result correction: The 15% fall after Q2 results offers a better entry point for investors who believe H2 launches will materialise.
Portfolio fit
Senores Pharmaceuticals offers exposure to the US complex generics opportunity through a fast-growing ANDA pipeline, rising controlled-substance launches and new manufacturing capacity. Successful launches, margin expansion and scaling of the US platform provide long-term growth prospects, while launch timing, regulatory approvals and working capital remain key monitorables.Senores Pharmaceuticals Ltd.: Budget 2026-27 opportunities
• Biopharma SHAKTI: The Budget announced a ₹10,000 crore programme over five years to build India’s biologics and biopharma ecosystem, supporting innovation-led pharmaceutical companies.
• Health Ministry Allocation: The Union Health Ministry received ₹1,06,530 crore, supporting demand for medicines and healthcare infrastructure.
• Customs Duty Exemptions: Basic customs duty was fully exempted on 17 life-saving drugs, mainly cancer therapies, and import duty relief was extended to seven additional rare diseases.
• Regulatory Strengthening: Measures to align approval timelines with global benchmarks can speed up approvals of complex products.
• Health Infrastructure: Higher allocations under PM-ABHIM and Ayushman Bharat PM-JAY (₹9,500 crore) support domestic healthcare demand.
Final thoughts
Senores Pharmaceuticals offers exposure to the US complex generics market through a rapidly expanding ANDA portfolio, a controlled-substance pipeline, new manufacturing capacity and a growing CDMO platform. Launches of approved products and expansion of its US platform provide additional avenues for growth as the company seeks to strengthen its position in the generic pharmaceutical value chain.
For investors evaluating Senores, the focus should be on the pace of ANDA launches, the timing of controlled-substance products, the sustainability of margins, the ramp-up of Apnar and the US ventures, and working-capital discipline. Regulatory approvals, pricing pressure, execution and capital-allocation decisions will remain key monitorables. A valuation assessment is essential before determining whether the stock offers an attractive investment opportunity.
